OBI Pharma geht AWK-Zusammenarbeit mit TegMine Therapeutics bei der Nutzung von GlycOBI® und TegMiner™ Enabling Technologies ein
Saturday, June 07, 2025
OBI Pharma, Inc. (OBI), a global clinical-stage oncology company specializing in the development of novel cancer therapies such as antibody-drug conjugates (ADCs) (4174.TWO), and TegMine Therapeutics, Inc. (TegMine), a US biopharmaceutical company developing first-in-class antibodies targeting cancer glycans and glycoproteins, have entered into an ADC-related master services agreement.
Under the agreement, OBI grants TegMine the rights to use OBI's GlycOBI® ADC technologies, based on EndoSymeOBI® and HYPrOBI® , to identify ADC treatment candidates for potential clinical development. Should one or more ADC product candidates emerge, OBI and TegMine will enter into a formal license agreement.
"This strategic collaboration leverages the synergistic strengths of both companies," said Dr. Heidi Wang, Chief Executive Officer of OBI Pharma. "We aim to advance OBI's compelling ADC products and leverage innovative ADC technologies such as GlycOBI® for a strategic partnership. We look forward to working closely with TegMine to generate new ADC candidates to treat patients with high unmet medical needs."
"This collaboration represents the exciting convergence of two innovative platforms," said Dr. Jeff Bernstein, Chief Executive Officer of TegMine Therapeutics. "OBI's ADC technology perfectly complements our efforts to target cancer-specific glycans. Together, we have the opportunity to develop ADCs with unprecedented tumor specificity and therapeutic efficacy."
About GlycOBI ®
OBI has developed a unique glycan-based ADC technology (GlycOBI ® ) available in a plug-and-play format and compatible with all antibodies, linkers, and drugs at various drug-antibody ratios (DARs). Using OBI's proprietary enzyme technology (EndoSymeOBI ® ) and linker technology (HYPrOBI TM ), GlycOBI ® produces site-specific, homogeneous ADCs in an efficient and scalable process under GMP conditions. GlycOBI ® 's conjugation process prevents disruption of the antibody structure and ensures that the ADC exhibits similar biophysical properties to the native antibody. Furthermore, OBI's linker technology has improved the payload conjugation efficiency and reduced aggregation tendency, significantly improving the manufacturing of ADC products. GlycOBI ® has overcome the limitations of conventional ADCs and demonstrated superior antitumor activity and stability in various animal studies.
About OBI Pharma
OBI is a global clinical-stage oncology company headquartered in Taiwan, founded in 2002. Together with its subsidiary OBI Pharma USA, Inc., it is committed to developing novel cancer medicines for patients with high unmet medical needs.
OBI is primarily focused on developing novel ADCs, including the first-generation cysteine-based TROP-2 ADC, OBI-992. Using its proprietary ADC technology GlycOBI® , based on EndoSymeOBI® and HYPrOBI™, OBI has developed a second generation of its innovative ADC pipeline, including monospecific ADCs such as OBI-902 (TROP-2), OBI-904 (Nectin-4), and trastuzumab ADC (HER2), as well as bispecific and dual-payload variants. To expand the applicability of the HYPrOBI™ linker technology, OBI has also developed a next-generation ThiOBI® platform enabling cysteine-based conjugation. OBI also has the first small molecule prodrug, OBI-3424, in its pipeline, targeting AKR1C3. This drug delivers a potent DNA-alkylating agent against tumors in the presence of the enzyme aldo-keto reductase 1C3 (AKR1C3), which is commonly expressed in tumors. For more information, please visit www.obipharma.com .
GlycOBI ® , EndoSymeOBI ® , and ThiOBI ® are registered trademarks of OBI. HYPrOBI™ is a registered trademark.
About TegMine Therapeutics
TegMine Therapeutics is a privately held biotechnology company based in San Francisco, California, USA, specializing in the development of antibody-based therapies targeting cancer-related glycans and glycoproteins. Founded in 2017, TegMine is pioneering a highly selective approach to cancer treatment, focusing on tumor-specific carbohydrate antigens that are virtually absent from healthy tissue. These novel targets are being developed into a diverse pipeline of antibody-drug conjugates (ADCs), bispecific antibodies, and cell therapies.
TegMine's proprietary TegMiner™ platform enables the discovery and development of therapeutic antibodies against previously inaccessible glycan epitopes, opening entirely new doors in oncology for patients with high medical needs.
For more information, please visit www.tegminetx.com
Forward-looking statements
Statements contained in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding future clinical trials, results, and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma's reports and presentations, including OBI Pharma's filings with the Taiwan Securities and Futures Commission.
Company Contacts:
Kevin Poulos, Chief Business Officer
OBI Pharma USA, Inc.
+1 (619) 537-7698, ext. 102
kpoulos@obipharma.com
Jeff Bernstein, CEO
TegMine Therapeutics, Inc.
operations@tegminetx.com
Source: globenewswire.com
